CJC-1295 (No DAC) vs 5-Amino-1MQ: Mechanism, Half-Life & Research Use

Direct Answer: How CJC-1295 (No DAC) and 5-Amino-1MQ Differ

CJC-1295 (No DAC) is a synthetic 29-amino-acid GHRH analog that stimulates pituitary somatotrophs to elevate pulsatile growth hormone and IGF-1 levels for tissue repair research. In contrast, 5-Amino-1MQ is a membrane-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), acting intracellularly to modulate SAM/NAD+ metabolic pathways rather than neuroendocrine hormone cascades.

While both research compounds are studied for their downstream effects on cellular metabolism and tissue maintenance, CJC-1295 (No DAC) operates through cell-surface G-protein coupled receptors (GPCRs), whereas 5-Amino-1MQ directly targets cytosolic enzyme activity.

Molecular Properties and Structural Classification

CJC-1295 (No DAC)—frequently designated in literature as Modified GRF 1-29—is a tetrasubstituted peptide derivative of natural growth hormone-releasing hormone. Its amino acid sequence incorporates substitutions at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, Leu27). These specific modifications protect the peptide backbone from rapid cleavage by dipeptidyl peptidase IV (DPP-IV) in blood plasma without requiring a Drug Affinity Complex (DAC) reactive group.

Conversely, 5-Amino-1MQ (5-amino-1-methylquinolinium) is a low-molecular-weight quinolinium-derived small molecule. Unlike peptide chains that require aqueous reconstitution and are vulnerable to enzymatic hydrolysis, 5-Amino-1MQ represents a stable organic compound designed to easily cross cell membranes. Laboratories investigating diverse target pathways can explore both small molecules and synthetic peptides across the PX1 catalog of all peptides and chemical reference standards.

Mechanism of Action: CJC-1295 (No DAC)

CJC-1295 (No DAC) acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on the anterior pituitary gland. Activation of GHRHR triggers the Gs alpha subunit, activating adenylate cyclase and boosting intracellular cyclic adenosine monophosphate (cAMP) concentrations. This intracellular cascade prompts the release of stored growth hormone (GH) in a natural, pulsatile fashion.

Preclinical literature demonstrates that as a GHRH analog, CJC-1295 (No DAC) is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research. Elevated circulating IGF-1 interacts with receptor tyrosine kinases in target tissues, upregulating protein synthesis via the PI3K/Akt/mTOR pathway and enhancing cellular recovery in rodent injury models.

Mechanism of Action: 5-Amino-1MQ

5-Amino-1MQ functions through a completely non-endocrine mechanism by inhibiting nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme predominantly expressed in adipose tissue, liver, and skeletal muscle. NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH).

By blocking NNMT enzymatic activity, 5-Amino-1MQ prevents the depletion of intracellular nicotinamide. This salvage mechanism increases available pools of nicotinamide adenine dinucleotide (NAD+) and SAM within the cell. Elevated NAD+ levels enhance sirtuin-1 (SIRT1) activation and poly(ADP-ribose) polymerase (PARP) function, promoting mitochondrial biogenesis, altered lipid metabolism, and increased basal metabolic rate in high-fat diet rodent models without directly affecting systemic pituitary hormone levels.

Pharmacokinetics, Half-Life, and Clearance Dynamics

The elimination half-life of CJC-1295 (No DAC) in rodent models ranges between 30 and 40 minutes following parenteral administration. This represents a significant extension over native GHRH (which exhibits a half-life of under 10 minutes), yet remains substantially shorter than CJC-1295 with DAC (which forms covalent bonds with serum albumin to persist for several days). Because CJC-1295 (No DAC) clears rapidly, it mimics physiologic pulse frequencies of endogenous GH release.

In contrast, 5-Amino-1MQ displays pharmacokinetic behavior characteristic of small lipophilic molecules. In animal models, oral or parenteral delivery yields systemic bio-availability with prolonged tissue accumulation, particularly within white adipose tissue. Pharmacokinetic assays indicate a terminal elimination half-life extending several hours, allowing sustained enzyme occupancy without requiring pulse-timing strategies.

Comparative Criteria Matrix

To assist laboratory researchers in selecting the correct model compound, the table below summarizes the key technical specifications of CJC-1295 (No DAC) and 5-Amino-1MQ:

| Criteria | CJC-1295 (No DAC) | 5-Amino-1MQ | | :--- | :--- | :--- | | **Mechanistic Class** | GHRH Receptor Agonist (Peptide) | NNMT Enzyme Inhibitor (Small Molecule) | | **Primary Target** | Pituitary GHRH Receptor | Cytosolic NNMT Enzyme | | **Reported Half-Life** | ~30–40 minutes (plasma) | Extended / Multi-hour tissue persistence | | **Solubility** | Aqueous buffers / Sterile Water | DMSO / Organic Solvents / Saline | | **Preclinical Models** | Rodent tissue repair, GH pulse assays | Diet-induced obesity, metabolic rate studies | | **Vial Sizes Available** | 2mg, 5mg, 10mg lyophilized powder | 50mg, 100mg reference powder |

This structural and functional divergence dictates distinct handling, preparation, and measurement methodologies in experimental protocols.

Comparative Research Applications in Preclinical Models

Selecting between these two compounds depends heavily on whether the study protocol focuses on neuroendocrine axis signaling or direct cellular energetics. In models examining connective tissue healing, bone density, or satellite cell recruitment in skeletal muscle, CJC-1295 (No DAC) is selected for its ability to activate systemic IGF-1 pathways.

Conversely, research protocols focused on obesity, metabolic syndrome, intracellular NAD+ depletion, or adipocyte hypertrophy utilize 5-Amino-1MQ to bypass receptor cross-talk and directly manipulate cellular energy dynamics.

When evaluating growth hormone axis secretagogues, researchers frequently compare CJC-1295 (No DAC) with related GHRH peptides such as Tesamorelin or ghrelin receptor agonists like Ipamorelin. While secretagogues operate via endocrine pathways, 5-Amino-1MQ provides a non-endocrine alternative for metabolic rate investigation.

Experimental Protocol Selection: Which Fits Your Study Design?

In vitro cell culture protocols investigating pituitary cell lines, chondrocyte proliferation, or myoblast differentiation generally require CJC-1295 (No DAC) to assess receptor-mediated transcriptional changes. Because of its targeted affinity for the GHRHR, it serves as a precise tool for isolating growth factor response elements.

For ex vivo adipose explants or primary cell cultures focusing on lipid storage, epigenetic methylation dynamics (via SAM preservation), or mitochondrial oxygen consumption rates, 5-Amino-1MQ is the appropriate molecular tool. Researchers running comparative metabolic studies may consult the PX1 research library hub to examine literature on pathway crosstalk.

Reconstitution, Buffer Compatibility, and Handling Guidelines

As a synthetic peptide, CJC-1295 (No DAC) is supplied as a lyophilized cake that must be reconstituted using sterile bacteriostatic water or standard phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear agitation during reconstitution to preserve secondary peptide conformation. Researchers can utilize the PX1 reconstitution calculator to determine precise volumetric concentrations for micro-dosing protocols in animal models.

5-Amino-1MQ, as a small molecule salt or free base, requires careful solvent consideration. While soluble in dimethysulfoxide (DMSO) and ethanol, working solutions for cell culture assays must be diluted into aqueous buffers while monitoring total solvent percentages to prevent cytotoxicity.

Quality Verification: Analytical Standards and COA Compliance

Reproducibility in preclinical research demands uncompromised purity and verified chemical composition. Impurities in peptide synthesis (such as truncated sequences) or unreacted intermediates in small-molecule synthesis can introduce confounding variables into cell signaling assays.

PX1 Research ensures that every batch of CJC-1295 (No DAC) and 5-Amino-1MQ undergoes rigorous analytical testing at ISO 17025 accredited facilities in the USA. Analytical evaluation includes High-Performance Liquid Chromatography (HPLC) to verify purity (>99%) and Mass Spectrometry (MS) to confirm exact molecular weight. Furthermore, bacterial endotoxin testing (LAL assay) is conducted on all lots to guarantee compliance with strict preclinical standards (<0.01 EU/mg). Batch-specific documentation is accessible directly via our public COA repository. Laboratories establishing bulk procurement protocols or institutional accounts can access specialized support via our wholesale portal.